[ad_1] Updated Jan. 11, 2024 12:47 pm ET Novartis has backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug…
Tag: NOVN.EB
WSJ News Exclusive | Novartis in Advanced Talks to Buy Cytokinetics
[ad_1] Updated Jan. 8, 2024 1:14 pm ET Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as big pharmaceutical companies continue to snap up…
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
[ad_1] Updated Dec. 26, 2023 12:33 pm ET Drug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio…
Novartis Raises Mid-Term Sales Growth Targets
[ad_1] Novartis lifted its sales growth guidance for the mid-term after what it called a progress in delivering its pure-play strategy. The Swiss pharmaceutical company upgraded on Tuesday its compound…
Novartis Raises Earnings Guidance After Key Drugs Boost Profit, Sales
[ad_1] Updated Oct. 24, 2023 3:04 am ET Novartis raised its full-year earnings guidance for the third time this year after it reported higher net profit and sales for the…
Big Pharma’s Battle With the Biden Administration Could Have Legs
[ad_1] Wall Street should pay attention as the pharma industry mounts a widening legal campaign against the Inflation Reduction Act. [ad_2] Source link
Seagen’s Cancer Therapy Is Making It a Takeover Target
[ad_1] Health Novel cancer agents could shore up aging pharmaceutical portfolios for big drugmakers [ad_2] Source link
WSJ News Exclusive | Pfizer in Talks to Acquire Seagen in Deal Likely Valued at More Than $30 Billion
[ad_1] WSJ News Exclusive Deals Potential deal would help the drug company add to its lineup of cancer treatments [ad_2] Source link